Patient satisfaction with adjustable transobturator male system in the Iberian multicenter study.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 25 11 2018
accepted: 10 01 2019
pubmed: 17 1 2019
medline: 20 2 2020
entrez: 17 1 2019
Statut: ppublish

Résumé

Patient-reported outcome measurements are important for urinary incontinence. We analyze self-assessed patient satisfaction and define the clinical profile of patient with highest satisfaction with the adjustable transobturator male system (ATOMS). Patient perception of results was evaluated in a series of 181 patients after ATOMS adjustment. Baseline incontinence severity was defined in pads-per-day (PPD) as mild (2), moderate (3-5) or severe (≥ 6), and dryness as use of none or one security PPD. Post-operative pain at discharge was evaluated by 0-10 visual analogue scale and complications by Clavien-Dindo classification. Multivariate analysis was performed to anticipate "very much better" than baseline perception on patient global impression of improvement and a predictive nomogram was developed. Dryness was achieved in 80.7% (94.9% mild, 80.8% moderate and 65.8% severe groups). Mean pad-test and pad-count decrease with respect to baseline was 458 ± 330 ml and 3.2 ± 1.9 PPD, respectively (both p < .0001). Complications presented in 25 (13.8%). The proportion of patients that self-declared satisfied with the procedure was 87.1%; 90.6% perceived their situation "better" and 48.1% "very much better" than before. Multivariate analysis revealed best perception is defined by dryness after adjustment (p < .0001), baseline severity of incontinence (p = .007), low post-operative pain at discharge (p = .0018) and lack of complications (p = .007). Self-assessed satisfaction with ATOMS is very high. Factors that predict best perception of improvement include dryness, baseline SUI severity, presence of complications and pain level during admission. Radiotherapy and device generation were not independent predictors. A nomogram to predict patients that are completely satisfied with ATOMS after adjustment is proposed.

Sections du résumé

BACKGROUNDS BACKGROUND
Patient-reported outcome measurements are important for urinary incontinence. We analyze self-assessed patient satisfaction and define the clinical profile of patient with highest satisfaction with the adjustable transobturator male system (ATOMS).
METHODS METHODS
Patient perception of results was evaluated in a series of 181 patients after ATOMS adjustment. Baseline incontinence severity was defined in pads-per-day (PPD) as mild (2), moderate (3-5) or severe (≥ 6), and dryness as use of none or one security PPD. Post-operative pain at discharge was evaluated by 0-10 visual analogue scale and complications by Clavien-Dindo classification. Multivariate analysis was performed to anticipate "very much better" than baseline perception on patient global impression of improvement and a predictive nomogram was developed.
RESULTS RESULTS
Dryness was achieved in 80.7% (94.9% mild, 80.8% moderate and 65.8% severe groups). Mean pad-test and pad-count decrease with respect to baseline was 458 ± 330 ml and 3.2 ± 1.9 PPD, respectively (both p < .0001). Complications presented in 25 (13.8%). The proportion of patients that self-declared satisfied with the procedure was 87.1%; 90.6% perceived their situation "better" and 48.1% "very much better" than before. Multivariate analysis revealed best perception is defined by dryness after adjustment (p < .0001), baseline severity of incontinence (p = .007), low post-operative pain at discharge (p = .0018) and lack of complications (p = .007).
CONCLUSIONS CONCLUSIONS
Self-assessed satisfaction with ATOMS is very high. Factors that predict best perception of improvement include dryness, baseline SUI severity, presence of complications and pain level during admission. Radiotherapy and device generation were not independent predictors. A nomogram to predict patients that are completely satisfied with ATOMS after adjustment is proposed.

Identifiants

pubmed: 30649591
doi: 10.1007/s00345-019-02639-4
pii: 10.1007/s00345-019-02639-4
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2189-2197

Références

Adv Ther. 2017 May;34(5):1173-1183
pubmed: 28405960
Neurourol Urodyn. 2017 Apr;36(4):927-934
pubmed: 28444702
World J Urol. 2019 Aug;37(8):1679-1686
pubmed: 30377812
Br J Cancer. 1988 Jan;57(1):109-12
pubmed: 3348942
GMS Interdiscip Plast Reconstr Surg DGPW. 2014 Dec 17;3:Doc15
pubmed: 26504726
J Urol. 2012 Jul;188(1):205-10
pubmed: 22591970
Can Urol Assoc J. 2008 Oct;2(5):536-9
pubmed: 18953453
Urol Int. 2018;101(1):106-113
pubmed: 29953998
Investig Clin Urol. 2016 Jan;57(1):3-13
pubmed: 26966721
J Urol. 2012 Mar;187(3):956-61
pubmed: 22264469
Ochsner J. 2006 Winter;6(2):54-8
pubmed: 21765794
J Urol. 1996 Dec;156(6):1975-80
pubmed: 8911369
Urology. 2018 Mar;113:13-19
pubmed: 29031841
Transl Androl Urol. 2017 Dec;6(6):1138-1143
pubmed: 29354501
J Urol. 2007 Apr;177(4):1414-8
pubmed: 17382743
World J Urol. 2017 Jan;35(1):145-151
pubmed: 27156092
Urology. 2016 Apr;90:189-94
pubmed: 26773347
J Urol. 2001 Aug;166(2):547-9
pubmed: 11458065
Cent European J Urol. 2014;67(4):387-91
pubmed: 25667760
J Urol. 1997 Aug;158(2):435-9
pubmed: 9224318
J Urol. 2014 Sep;192(3):836-42
pubmed: 24650425
Eur Urol. 2013 Apr;63(4):681-9
pubmed: 23219375
J Urol. 2016 Sep;196(3):838-43
pubmed: 26997310
J Urol. 2002 Sep;168(3):896-905
pubmed: 12187188
Neurourol Urodyn. 2007;26(1):8-13
pubmed: 17016797
Can Urol Assoc J. 2011 Aug;5(4):268-72
pubmed: 21251472
Adv Ther. 2019 Feb;36(2):426-441
pubmed: 30560525
J Urol. 2001 Nov;166(5):1755-8
pubmed: 11586217
BJU Int. 2017 May;119(5):785-792
pubmed: 27868328
Neurourol Urodyn. 2018 Apr;37(4):1458-1466
pubmed: 29315765
BJU Int. 2013 Feb;111(2):296-303
pubmed: 23186285

Auteurs

Javier C Angulo (JC)

Departamento Clínico, Hospital Universitario de Getafe, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Carretera de Toledo Km 12.5, Getafe, 28905, Madrid, Spain. jangulo@futurnet.es.

Ignacio Arance (I)

Departamento Clínico, Hospital Universitario de Getafe, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Carretera de Toledo Km 12.5, Getafe, 28905, Madrid, Spain.

Antonio Ojea (A)

Hospital Alvaro Cunqueiro, Vigo, Spain.

Manuel Carballo (M)

Hospital Alvaro Cunqueiro, Vigo, Spain.

Andrés Rodríguez (A)

Hospital Arquitecto Marcide, Ferrol, Spain.

Javier Pereira (J)

Hospital Arquitecto Marcide, Ferrol, Spain.

Miguel Rebassa (M)

Hospital Son Llatzer, Palma de Mallorca, Spain.

Antoine Teyrouz (A)

Hospital Son Llatzer, Palma de Mallorca, Spain.

Gregorio Escribano (G)

Hospital Universitario Gregorio Marañón, Madrid, Spain.

Fernando Teba (F)

Hospital Universitario de la Princesa, Madrid, Spain.

Blanca Madurga (B)

Hospital Universitario Puerta del Mar, Cádiz, Spain.

Francisco E Martins (FE)

Hospital de Santa María, Lisbon, Portugal.

Francisco Cruz (F)

Centro Hospitalar São João, Oporto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH